Clinical Implications of Intestinal Barrier Damage in Psoriasis

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2021 Feb 5

PMID 33542642

Citations 12

Authors

Mariusz Sikora

Albert Stec

Magdalena Chrabaszcz

Joanna Giebultowicz

Emilia Samborowska

Radoslaw Jazwiec

Michal Dadlez

Malgorzata Olszewska

Lidia Rudnicka

Affiliations

Soon will be listed here.

Abstract

Background: An increasing amount of evidence suggests an association between increased intestinal permeability and the pathogenesis of chronic inflammatory diseases. However, the clinical significance of gut barrier dysfunction in psoriasis remains to be established.

Objective: To evaluate whether there are differences in disease activity, the severity of gastrointestinal symptoms and the blood concentration of bacterial metabolites in psoriatic patients with a normal and altered intestinal barrier.

Patients And Methods: Gut barrier integrity was assessed with the serum concentrations of claudin-3, a modulator of intestinal tight junctions and an intestinal fatty acid-binding protein, a marker of enterocyte damage. Gastrointestinal symptoms were evaluated with a validated questionnaire. The concentration of trimethylamine N-oxide (TMAO), a gut microbiota-associated metabolite, was measured with high-performance liquid chromatography.

Results: One hundred and fourteen patients with psoriasis were finally enrolled in the study - 68 with an altered gut barrier and 46 with a properly functioning intestinal barrier. Patients with an altered gut barrier showed a significantly higher score in the Gastrointestinal Symptom Rating Scale (3.20 vs 1.46, p<0.001). Moreover, patients with psoriasis and a disrupted intestinal barrier demonstrated a higher disease activity (PASI: 19.7 vs 10.3, p<0.001) and systemic inflammatory parameters (neutrophil-to-lymphocyte ratio: 2.86 vs 1.71, p<0.001; C-reactive protein 3.76 vs 1.92; p<0.05). The marker of bacterial translocation was significantly higher in psoriatic patients with damaged gut integrity (TMAO: 375.7±51.9 vs 119.4±27.5 ng/mL; p<0.05).

Conclusion: The altered gut barrier in psoriasis is associated with gastrointestinal symptoms, systemic inflammatory profile and the increased blood concentration of gut microbiota-derived metabolite - TMAO. Intestinal barrier modulation represents a new promising therapeutic approach.

Citing Articles

Probiotic Supplements Benefit Psoriasis Therapy Rather Than Affecting Disease Risk: Evidence from NHANES Machine-Learning and Meta-Analysis Study.

Li Y, Liu X, Cao Z, Wu J Probiotics Antimicrob Proteins. 2024; .

PMID: 39652292 DOI: 10.1007/s12602-024-10418-w.

Advances in psoriasis and gut microorganisms with co-metabolites.

Zhu Q, Wu K, Yang Q, Meng B, Niu Y, Zhao F Front Microbiol. 2023; 14:1192543.

PMID: 38033573 PMC: 10687559. DOI: 10.3389/fmicb.2023.1192543.

The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity.

Reali E, Caliceti C, Lorenzini A, Rizzo P Inflammation. 2023; 47(1):13-29.

PMID: 37953417 PMC: 10799147. DOI: 10.1007/s10753-023-01915-1.

Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets.

Tie Y, Huang Y, Chen R, Li L, Chen M, Zhang S Gut Microbes. 2023; 15(2):2265028.

PMID: 37822139 PMC: 10572083. DOI: 10.1080/19490976.2023.2265028.

Impaired intestinal permeability in patients with multiple sclerosis.

Fialova L, Barilly P, Stetkarova I, Bartos A, Noskova L, Zimova D Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023; 169(1):37-43.

PMID: 37581230 DOI: 10.5507/bp.2023.033.

References

Sikora M, Chrabaszcz M, Waskiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L . Claudin-3 - a new intestinal integrity marker in patients with psoriasis: association with disease severity. J Eur Acad Dermatol Venereol. 2019; 33(10):1907-1912. DOI: 10.1111/jdv.15700. View

Codoner F, Ramirez-Bosca A, Climent E, Carrion-Gutierrez M, Guerrero M, Perez-Orquin J . Gut microbial composition in patients with psoriasis. Sci Rep. 2018; 8(1):3812. PMC: 5830498. DOI: 10.1038/s41598-018-22125-y. View

Richetta A, Grassi S, Moliterni E, Chello C, Calvieri C, Carnevale R . Increased intestinal barrier permeability in patients with moderate to severe plaque-type psoriasis. J Dermatol. 2020; 47(10):e366-e368. DOI: 10.1111/1346-8138.15361. View

Stehlikova Z, Kostovcik M, Kostovcikova K, Kverka M, Juzlova K, Rob F . Dysbiosis of Skin Microbiota in Psoriatic Patients: Co-occurrence of Fungal and Bacterial Communities. Front Microbiol. 2019; 10:438. PMC: 6437110. DOI: 10.3389/fmicb.2019.00438. View

Farhangi M, Vajdi M . Novel findings of the association between gut microbiota-derived metabolite trimethylamine oxide and inflammation: results from a systematic review and dose-response meta-analysis. Crit Rev Food Sci Nutr. 2020; 60(16):2801-2823. DOI: 10.1080/10408398.2020.1770199. View

Adarsh M, Dogra S, Vaiphei K, Vaishnavi C, Sinha S, Sharma A . Evaluation of subclinical gut inflammation using faecal calprotectin levels and colonic mucosal biopsy in patients with psoriasis and psoriatic arthritis. Br J Dermatol. 2019; 181(2):401-402. DOI: 10.1111/bjd.17745. View

Ufnal M, Zadlo A, Ostaszewski R . TMAO: A small molecule of great expectations. Nutrition. 2015; 31(11-12):1317-23. DOI: 10.1016/j.nut.2015.05.006. View

Jaworska K, Bielinska K, Gawrys-Kopczynska M, Ufnal M . TMA (trimethylamine), but not its oxide TMAO (trimethylamine-oxide), exerts haemodynamic effects: implications for interpretation of cardiovascular actions of gut microbiome. Cardiovasc Res. 2019; 115(14):1948-1949. DOI: 10.1093/cvr/cvz231. View

Ramirez-Bosca A, Navarro-Lopez V, Martinez-Andres A, Such J, Frances R, Horga de la Parte J . Identification of Bacterial DNA in the Peripheral Blood of Patients With Active Psoriasis. JAMA Dermatol. 2015; 151(6):670-1. DOI: 10.1001/jamadermatol.2014.5585. View

10.

Papandreou C, More M, Bellamine A . Trimethylamine N-Oxide in Relation to Cardiometabolic Health-Cause or Effect?. Nutrients. 2020; 12(5). PMC: 7284902. DOI: 10.3390/nu12051330. View

11.

Tilg H, Zmora N, Adolph T, Elinav E . The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2019; 20(1):40-54. DOI: 10.1038/s41577-019-0198-4. View

12.

Roy S, Yuzefpolskaya M, Nandakumar R, Colombo P, Demmer R . Plasma Trimethylamine-N-oxide and impaired glucose regulation: Results from The Oral Infections, Glucose Intolerance and Insulin Resistance Study (ORIGINS). PLoS One. 2020; 15(1):e0227482. PMC: 6961885. DOI: 10.1371/journal.pone.0227482. View

13.

Tong Y, Marion T, Schett G, Luo Y, Liu Y . Microbiota and metabolites in rheumatic diseases. Autoimmun Rev. 2020; 19(8):102530. DOI: 10.1016/j.autrev.2020.102530. View

14.

Sikora M, Stec A, Chrabaszcz M, Knot A, Waskiel-Burnat A, Rakowska A . Gut Microbiome in Psoriasis: An Updated Review. Pathogens. 2020; 9(6). PMC: 7350295. DOI: 10.3390/pathogens9060463. View

15.

Wolyniec W, Kasprowicz K, Giebultowicz J, Korytowska N, Zorena K, Bartoszewicz M . Changes in Water Soluble Uremic Toxins and Urinary Acute Kidney Injury Biomarkers After 10- and 100-km Runs. Int J Environ Res Public Health. 2019; 16(21). PMC: 6862582. DOI: 10.3390/ijerph16214153. View

16.

Sikora M, Chrabaszcz M, Maciejewski C, Zaremba M, Waskiel A, Olszewska M . Intestinal barrier integrity in patients with plaque psoriasis. J Dermatol. 2018; 45(12):1468-1470. DOI: 10.1111/1346-8138.14647. View

17.

Kulich K, Madisch A, Pacini F, Pique J, Regula J, van Rensburg C . Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: a six-country study. Health Qual Life Outcomes. 2008; 6:12. PMC: 2276197. DOI: 10.1186/1477-7525-6-12. View

18.

Sikora M, Stec A, Chrabaszcz M, Waskiel-Burnat A, Zaremba M, Olszewska M . Intestinal Fatty Acid Binding Protein, a Biomarker of Intestinal Barrier, is Associated with Severity of Psoriasis. J Clin Med. 2019; 8(7). PMC: 6678629. DOI: 10.3390/jcm8071021. View

19.

Yang S, Li X, Yang F, Zhao R, Pan X, Liang J . Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target. Front Pharmacol. 2019; 10:1360. PMC: 6877687. DOI: 10.3389/fphar.2019.01360. View

20.

Feldman S, Srivastava B, Abell J, Hoops T, Fakharzadeh S, Chakravarty S . Gastrointestinal Signs and Symptoms Related to Inflammatory Bowel Disease in Patients With Moderate-to-Severe Psoriasis. J Drugs Dermatol. 2018; 17(12):1298-1308. View